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Background. APOBEC3G (apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G) has antiretroviral activity
associated with the hypermutation of viral DNA through cytosine deamination. APOBEC3G has two cytosine deaminase (CDA)
domains; the catalytically inactive amino-terminal domain of APOBEC3G (N-CDA) carries the Vif interaction domain. There is no
3-D structure of APOBEC3G solved by X-ray or nuclear magnetic resonance. Methodology/Principal Findings. We predicted
the structure of human APOBEC3G based on the crystal structure of APOBEC2. To assess the model structure, we evaluated 48
mutants of APOBEC3G N-CDA that identify novel variants altering DVif HIV-1 infectivity and packaging of APOBEC3G. Results
indicated that the key residue D128 is exposed at the surface of the model, with a negative local electrostatic potential.
Mutation D128K changes the sign of that local potential. In addition, two novel functionally relevant residues that result in
defective APOBEC3G encapsidation, R122 and W127, cluster at the surface. Conclusions/Significance. The structure model
identifies a cluster of residues important for packaging of APOBEC3G into virions, and may serve to guide functional analysis of
APOBEC3G.
Citation: Zhang K-L, Mangeat B, Ortiz M, Zoete V, Trono D, et al (2007) Model Structure of Human APOBEC3G. PLoS ONE 2(4): e378. doi:10.1371/
journal.pone.0000378
INTRODUCTION
Primate APOBEC3G has antiretroviral activity associated with the
hypermutation of viral DNA through cytosine deamination (for
recent review see [1–3]). Human APOBEC3G (huAPOBEC3G)
fails to restrict HIV-1 due to the degradation imposed by the HIV-
1 Vif [4]. In contrast, a number of primate APOBEC3G orthologs
display activity against HIV-1 [5–8]. APOBEC3G has a duplicated
catalytic deaminase domain (CDA); the amino-terminal domain
(N-CDA) of APOBEC3G is required for viral encapsidation but
not cytosine deamination [9–11].
There is no 3-D structure solved by X-ray or NMR nor an
accurate model of APOBEC3G available. APOBEC3G relates to
APOBEC family and AID (activation-induced deaminase) at the
sequence level. Recent comparative modeling work for APOBEC-
1 and AID [12–17] led to the proposition of a secondary structure
alignment between APOBEC3G and cytidine deaminase [18].
The recent publishing of the crystal structure of APOBEC2 [19]
provides the template to build a reliable model structure of
APOBEC3G by theoretical methods.
In the present work, we model human APOBEC3G, with
particular emphasis on the N-terminal domain. Using mutant data
of the N-CDA, we mapped critical residues for packaging of
APOBEC3G into viral particles on the new structure model of the
huAPOBEC3G N-CDA. We completed the analysis by mapping
N-CDA residues that are under positive evolutionary pressure in
primate APOBEC3G.
While this work was concluded, Huthoff and Malim provided
a detailed molecular genetic analysis of the N-CDA region
spanning amino acids residues 119 to 146 (Ref [20]). This analysis
defined residues 124 to 127 as having a role in APOBEC3G
packaging into HIV-1 virions, and residues 128 to 130 as crucial
for the interaction with HIV-1 Vif. Our current results confirm
and extend this work, and place the findings in a detailed
structural model that may serve to advance rational drug design.
MATERIALS AND METHODS
Target sequence and template for structural model
The huAPOBEC3G sequence (residues 1-384; NCBI accession:
NP_068594, see http://www.ncbi.nih.gov/) was defined as target
sequence. The newly crystallized Human APOBEC2 dimer [19]
(PDB ID 2NYT obtained from Xiaojiang S. Chen, see http://
www.rcsb.org/pdb/Welcome.do) served as template.
Target-template alignment
We used the align2d function of MODELLER program (http://
salilab.org/modeller/) [21–23], to align huAPOBEC3G N-CDA
sequence (residues 1-194) and huAPOBEC3G C-CDA sequence
(residues 195-384) to the huAPOBEC2 dimer. Additional
assessment of the target-template alignment compared structurally
determined (DSSP, http://bioweb.pasteur.fr/seqanal/interfaces/
dssp-simple.html) [24] and predicted (PSIPRED, http://bioinf.cs.
ucl.ac.uk/psipred/) [25–27] secondary structures. The alignment
was analyzed and viewed by Jalview (http://www.jalview.org/)
[28].
Model building, evaluation and mapping of key
residues
The target-template alignment was used to build the model by
satisfaction of spatial restraints. The ANOLEA program (http://
swissmodel.expasy.org/anolea/) [29–31], that estimates the fold-
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ing free energy of each residue of a protein chain to assess the
quality of the predicted structure, was used to score all the models,
using the default 5 residue window averaging.
The geometry of the active site/pseudo-active site was based on
the corresponding homologous active site regions of the huAPO-
BEC2 template. The main interaction of anti-parallel b2-b29,
between huAPOBEC3G N-CDA and C-CDA was defined by
restraining segments 48-56 and 235-243 as anti-parallel b-sheet,
based on the huAPOBEC2 dimer. For the chain connection
between N-CDA and C-CDA, the first 20 amino acid residues of
C-CDA were used as a linker and modeled ab initio using the loop
routine of the MODELER program.
Generation of 100 models allowed selection of the best model
candidate based on the global ANOLEA score. Final refinement
for alignment of gap regions was performed by generating 100
additional models, followed by selection of the best model on the
basis of the ANOLEA score. The final model was energy-
minimized using the CHARMM program (http://www.charmm.
org/) [32] and the CHARMM22 all atom force field [33]. The
minimization consisted of 200 steps of steepest descent using
a dielectric constant of 1 and the Generalized Born GB-MV2
implicit solvent model without cutoff for the solvation free energy.
Model evaluation was based on ANOLEA with window 5
averaging, as described above.
Figure 1. Ribbon view of the huAPOBEC2 dimer and the model of huAPOBEC3G. Panel A. The APOBEC2 ‘‘homo’’-dimer. Panel B. The huAPOBEC3G
model underscoring the six active and pseudo-active site residues in blue, the two zinc ions, and the position of the residue D128, key in the
interaction with HIV-1 Vif.
doi:10.1371/journal.pone.0000378.g001
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The CHARMM program was used to calculate the solvent
accessible surface area of the final model. Additionally, using the
FoldX program (http://foldx.embl.de/) [34], in silico alanine-
scanning was performed by mutating each residue and calculated
the change of folding energy. Molecular surface visualization was
done using Chimera (http://www.cgl.ucsf.edu/chimera/) [35,36].
The surface was color-coded according to the Poisson-Boltzmann
potential calculated by the UHBD program [37].
Mutation analysis, constructs, viral production and
titration
The plasmid expressing a hemagglutinin (HA)-tagged form of
APOBEC3G was a kind gift from M. Malim. A series of
APOBEC3G alanine and specific mutants was constructed with
the QuickChange Mutagenesis kit (Stratagene). The collection was
already constituted, and it was not defined on the basis of the new
structural data. HIV-1 particles were produced by transient
transfection of 293T cells with Fugene (Roche) of a wild-type or of
a Vif-defective HIV-1 proviral clone. Viral titers were determined
in single-round infectivity assays by applying filtered supernatant
from producer cells on HeLa-CD4-LTRLacZ indicator cells.
Virion infectivity was derived by dividing the infectious titer by the
amount of physical particles.
Packaging assay and Western Blots
HIV-1 particles were produced by transient transfection of 293T
cells with Fugene (Roche). 1 ml of virus was then spun in
Eppendorf tubes at 13’000rpm in a microfuge at 4u for
90 minutes, without sucrose cushion. Pellets were resuspended in
PBS 1% Triton, and the virion amount was measured by
a standard RT assay. Normalized amount of virions were then
loaded on standard Laemmli protein gels to perform Western
Blots. Cell extracts were obtained through a standard RIPA
extraction procedure. The HA tag was detected with the mouse
hrp-coupled anti-HA 3F10 antibody (Roche). PCNA (proliferating
cell nuclear antigen) was detected with the mouse Ab-1 antibody
(Oncogene Science). The HIV-1 capsid was detected with the
murine anti-p24 antibody produced from the AIDS Research and
Reference Reagent Program #183-H12-5C.
RESULTS
The huAPOBEC2 tetramer is composed of two outer monomers
and two middle monomers. The outer and middle monomers
share the same sequence but a slightly different structure in the
region of residues 57-68. For an outer monomer, this region is
a hairpin-loop; but for a middle monomer this region is a loop
with residue E60 coordinating with Zn2+ [19], Fig. 1A. We
modeled the huAPOBEC3G N-CDA based on the outer mono-
mer of APOBEC2 to resolve the structure between residues 22 and
33 of huAPOBEC3G. The outer monomer of APOBEC2 is more
suitable as template because the middle monomer coordinates the
Zn2+ with E60, a residue not present at the corresponding position
in huAPOBEC3G N-CDA. The corresponding region of huA-
POBEC3G C-CDA was modeled ab initio. The target-template
alignment generated by MODELLER agreed with the secondary
structure alignment (Supplementary Fig. S1A). The resulting
huAPOBEC3G model is shown in Fig. 1B. The structural pattern
of this model is very similar to that of the huAPOBEC2 dimer.
The final model has a good ANOLEA score profile (indicating
reliability of the structure prediction) with a pattern comparable to
that of huAPOBEC2 dimer despite the low sequence identity
(27%), Supplementary Fig. S1.
Table 1. Mutation, antiviral activity, and surface exposure of
residues of the huAPOBEC3G N-CDA.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anti-HIV
activity*
Protein
expression**
Solvent Accessible
Surface Area ***
Y13A +++ +++ 14.1+0
F17L +++ +++ 2.4+0.3
F21L +++ +++ 0.4+0
S28A ++ +++ 73.9+17.3
R29A +++ +++ 187.2+0
T32A ++ ++ 6.5+0
Y37A +++ +++ 0+0
K40A + + 76.0+0.2
S45A ++ ++ 33.9+9.5
L49A +++ +++ 24.8+0
L62A +++ +++ 50.1+4.3
H65R + + 7.5+0
E67Q + + 0+0
F70L 0 ++ 0.2+0
F74L ++ +++ 151.5+15.0
E85Q +++ +++ 104.9+0
Y86A +++ +++ 16.3+0.8
W90L +++ ND 0+0
Y91A 0 ++ 16.7+0
I92V +++ ND 0.1+0
S93A +++ +++ 0+0
W94L + +++ 35.0+0
P96L ++ ++ 0+0
C97S + + 15.0+1.5
C100S + + 0+0.2
M104A +++ +++ 0+0
F107L +++ +++ 23.6+0
L108A ++ ++ 2.5+0.6
L116A ++ ++ 0.5+0
T117A +++ +++ 19.1+0
I118A ++ + 0+0
R122A 0 ++ 76.6+0
L123A ++ ++ 0+1.6
Y124A + +++ 36.1+0.7
Y125A +++ +++ 138.6+6.4
F126L +++ +++ 22.6+0
W127L 0 ++ 187.3+17.8
D130K/N +++ +++ 88.7+2.1
Y131V ++ ++ 2.2+0
E133Q +++ +++ 112.3+4.9
L135A +++ +++ 0+0
L138A ++ ++ 0+0
M152A ++ ++ 0+0
Y154A ++ +++ 120.7+0
F157L ++ +++ 4.4+0
C160S +++ +++ 0.2+0
F164L ++ ++ 0+0
Novel functional residues that abolish huAPOBEC3G antiviral activity against wild-type HIV-1
infection are highlighted bold.
*
0= no activity, +residual activity (,10% of wild type),++modest activity (10–50%), +++full
activity.
**
Semiquantitative western blot
***
Estimated by side chain+backbone. Values greater than 20 suggest that the residue is
exposed at the surface.
doi:10.1371/journal.pone.0000378.t001
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Mutation analysis and mapping of key functional
residues
Mutation analysis interrogated 48 of 194 (25%) residues of the
huAPOBEC3G N-CDA (Table 1). Mutation of the conserved
residues constituting the N-CDA Zn2+ coordination domain H65,
C97 and C100 prevented or reduced encapsidation as previously
reported [9]. Mutation of residues F70 and Y91, shown to mediate
RNA binding [38], was associated with reduced APOBEC3G
encapsidation, as previously reported [9]. Mutation of the pseudo-
catalytic site residue E67 (E67Q), resulted in poor protein
expression, which limited functional evaluation; E67A was
previously reported to reduce the rates of APOBEC3G encapsida-
tion into HIV1 virions [9]. E67 and F70 are buried inside of the
model; E67A and F70A may affect folding stability (in silico
alanine-scanning). Y91 is a partially exposed at the surface.
Amino acids substitutions at positions Y13, F17, F21, R29, T32,
Y37, K40, S45, L49, L62, E85, Y86, W90, I92, S93, P96, M104,
F107, L108, L116, T117, I118, L123, Y125, F126, D130, Y131,
E133, L135, L138, M152, C160 and F164 did not result in
changes in anti-viral activity. Mutations S28A, F74L, W94L,
Y124A, Y154A resulted in reduced inhibition of DVif HIV1, while
mutations R122A and W127L completely abolished this activity
(Table 1). The functionally defective phenotype of these mutants
correlated with a failure to become encapsidated into DVif HIV-1
particles (Fig. 2). R122, W127 and D128 form a cluster at the
surface (Fig. 3) and contribute to changes in surface charge or
structure (Fig. 4).
Prior evolutionary analysis of primate APOBEC3G identified
a number of residues under diversifying (positive) selection [39].
Most of the residues under positive selection pressure are exposed
at the surface of the model. A cluster of residues under positive
selection that includes T98, K99, R102, D128, and P129 overlaps
with the cluster of functionally important residues around D128
(Fig. 3).
DISCUSSION
This work presents a model structure of huAPOBEC3G that
captures information from the recently published APOBEC2
structure [19]. Critically, the APOBEC2 template provides
a structural reference for the predicted extra helix a4, that carries
residue D128–a residue that governs the virus-specific sensitivity of
APOBEC3G to Vif-mediated inhibition [5–8]. Previously avail-
able CDA structures provided suboptimal templates for APO-
BEC3G N-CDA. This is not only due to the low sequence identity,
Figure 2. Infectivity, and packaging assay of novel defective huAPOBEC3G mutants. Panel A. D Vif HIV-1 particles were produced in presence of
different doses of wt APOBEC3G-HA (A3G), or with the highest dose of the R122A and W127L mutants of APOBEC3G-HA. The infectivity of these
particles was determined by titration on P4.2 indicator cells. The doses d1 to d4 of APOBEC3G correspond respectively to a molar ratio of APOBEC3G-
HA plasmid to virus plasmid of 0.6:1, 1.3:1, 2.7:1 and 5.5:1. The graph is made from one duplicate experiment, and is representative of a total of at
least 4 independent duplicate experiments. Panel B. The presence of wt APOBEC3G-HA or the R122A and W127L mutants in DVif HIV-1 virions was
assessed by western blot. The PCNA and capsid western blots serve to check for consistent loading of cellular and virion extracts, respectively.
Representative of at least two independent experiments.
doi:10.1371/journal.pone.0000378.g002
APOBEC3G Structure
PLoS ONE | www.plosone.org 4 April 2007 | Issue 4 | e378
but also because of the presence in APOBEC3G N-CDA of an
extra a helix. In contrast, APOBEC2 has an extra a helix, resulting
in a a1-b1-b2-a2-b3-a3-b4-a4-b5-a5-a6 configuration, while
CDA structures such as human cytidine deaminase have the
pattern a1-b1-b2-a2-b3-a3-b4-b5-a4-a5. In addition, the direc-
tion of b4 and b5 are different: parallel in APOBEC2 but anti-
parallel in cytidine deaminase. We had previously used the yeast
Cytosine deaminase (PDB ID 1P6O, chain A) to address the
position of the extra helix and the correct direction of b4 and b5.
The model emerging from this analysis allows speculation on
various functionally relevant structural details of interest for the
understanding of the Vif-APOBEC3G interaction and the process
of APOBEC3G encapsidation into HIV-1 virions. In contrast with
previous secondary and tertiary structure models, the current
model locates the distinctive extra alpha helix on the same planar
surface as the pseudo-active site. We evaluated extensive mutation
data on this surface, that characterized two functionally relevant
residues R122 and W127 that resulted in failure to inhibit
infection by HIV-1/Dvif due to lack of packaging of APOBEC3G
into viral particles. Interaction of APOBEC3G with the NC-
domain of HIV-1 Gag and non-specific RNA binding leads to its
encapsidation into progeny virions [10,40–43]. The structural
model proposes a surface hot-spot domain that includes residues
R122, W127 in proximity to the active site, and overlapping with
a cluster of residues under positive selective pressure that includes
D128 and P129.
Figure 3. Mapping of functional and evolutionary informative residues at the molecular surface of N-CDA. Panel A, Mapping of functional
residues. The color gradient (dark red.red.orange.yellow) reflects the role of various mutations in abolishing anti-HIV activity (see Table 1) ranging
from no antiviral activity (dark red) to normal activity (yellow). Panel B. Mapping of evolutionary informative residues at the molecular surface. Green
color identifies amino acids under positive selective pressure in primate APOBEC3G. The positive selection cluster includes T98, K99, R102, D128, and
P129. Blue color identifies the pseudo–active site.
doi:10.1371/journal.pone.0000378.g003
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Our results are consistent with the work of Huthoff and Malim
[20]. While their work concentrated on the molecular genetic
analysis of the 28-amino acid region between residues 119 and
146, our analysis interrogated 48 of the 194 residues of the N-
CDA domain. This reflects the interest to identify additional
motifs capable of interacting with HIV-1 Vif, or participating in
packaging [20,44]. Minor differences were observed between the
two studies. We observed a defect in the packaging efficiency of
R122A mutant protein–that extends the relevant motif to include
R122-Y124-Y125-F126-W127. Regarding the motif affecting
regulation by Vif, our analysis of D130 mutants (D130K and
D130N) did not result in a Vif-resistant phenotype. This difference
may reflect a greater dependence of the N-CDA and Vif for the
negative charge in position 128 (Ref [20]). While not formally
tested in the present study, the biological relevance of P129 is
highlighted by its inclusion–together with D128-in a patch of
residues under positive selective pressure in primates.
Inspection of surface modifications conferred by various
mutations highlights the structural and/or charge differences in
this region as the molecular basis for disruption of the
APOBEC3G packaging into HIV-1 virions, and modification in
the interaction with Vif. The detailed model structure presented
here could serve to advance rational drug design. The quality of
a homology model is strongly related to the sequence identity with
the structural template. The current model, based on a sequence
identity of 27%, should be satisfactory in its global fold, as
supported by the good ANOLEA energy score profile (Supple-
mentary Fig. S1). From such a model, correct positioning of the
protein backbone and orientation of the side chains can be
expected, allowing reliable conclusion to be made in the design
and interpretation of experimental mutation data. Whether or not
the accuracy of such a model is sufficient to perform docking
simulations is still an open question. However, the fact that critical
residues obtained experimentally by mutation analysis do cluster
in well-defined patches at the surface of the model argue that side
chain packing is correct. In the latter case, docking simulations
could be envisioned based on the current model. As recently
shown for TRIM5a [45], the model proposed may serve to guide
further functional analysis of APOBEC3G.
SUPPORTING INFORMATION
Figure S1 Panel A, Target-template alignment. Alpha helix are
shown in red and beta sheets in green. The huAPOBEC3G N-
CDA is aligned to the outer (O) monomer of APOBEC2, and the
C-CDA to the middle (M) monomer. Panel B, ANOLEA scores.
The three ANOLEA profiles and the secondary structure were
aligned according to the target-template alignment. The ANO-
LEA profile excludes the uncharacterized linker (residues 195-214)
Found at: doi:10.1371/journal.pone.0000378.s001 (2.86 MB EPS)
ACKNOWLEDGMENTS
We thank X.S. Chen for APOBEC2 PDB data.
Author Contributions
Conceived and designed the experiments: AT DT OM. Performed the
experiments: KZ BM. Analyzed the data: AT DT MO KZ BM OM.
Contributed reagents/materials/analysis tools: VZ OM. Wrote the paper:
AT KZ OM.
Figure 4. Mapping potential to molecular surface. Zoomed in view on the functional surface region within the N-CDA. Panel A, wild-type
huAPOBEC3G N-CDA. Panel B-D, effect of mutations R122A, W127L, and D128K on surface charge and shape. The red color represents negative
potential, the blue color expresses positive potential, and the white color expresses zero potential.
doi:10.1371/journal.pone.0000378.g004
APOBEC3G Structure
PLoS ONE | www.plosone.org 6 April 2007 | Issue 4 | e378
REFERENCES
1. Cullen BR (2006) Role and mechanism of action of the APOBEC3 family of
antiretroviral resistance factors. J Virol 80: 1067–1076.
2. Yu X-F (2006) Innate cellular defenses of APOBEC3 cytidine deaminases and
viral counter-defenses. Curr Opin HIV/AIDS 1: 187–193.
3. Harris RS, Matsuo H (2006) Dancin’ deaminase. Nat Struct Mol Biol 13:
380–381.
4. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene
that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature
418: 646–650.
5. Mangeat B, Turelli P, Liao S, Trono D (2004) A single amino acid determinant
governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem
279: 14481–14483.
6. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR (2004) A single amino acid
difference in the host APOBEC3G protein controls the primate species
specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci U S A
101: 3770–3774.
7. Schrofelbauer B, Chen D, Landau NR (2004) A single amino acid of
APOBEC3G controls its species-specific interaction with virion infectivity factor
(Vif). Proc Natl Acad Sci U S A 101: 3927–3932.
8. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, et al. (2004) A single amino
acid substitution in human APOBEC3G antiretroviral enzyme confers resistance
to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A
101: 5652–5657.
9. Navarro F, Bollman B, Chen H, Konig R, Yu Q, et al. (2005) Complementary
function of the two catalytic domains of APOBEC3G. Virology 333: 374–386.
10. Luo K, Liu B, Xiao Z, Yu Y, Yu X, et al. (2004) Amino-terminal region of the
human immunodeficiency virus type 1 nucleocapsid is required for human
APOBEC3G packaging. J Virol 78: 11841–11852.
11. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, et al. (2005)
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase
activity. Curr Biol 15: 166–170.
12. Scott J, Navaratnam N, Carter C (1998) Molecular modelling and the
biosynthesis of apolipoprotein B containing lipoproteins. Atherosclerosis 141
Suppl 1: S17–S24.
13. Navaratnam N, Fujino T, Bayliss J, Jarmuz A, How A, et al. (1998) Escherichia
coli cytidine deaminase provides a molecular model for ApoB RNA editing and
a mechanism for RNA substrate recognition. J Mol Biol 275: 695–714.
14. Xie K, Sowden MP, Dance GS, Torelli AT, Smith HC, et al. (2004) The
structure of a yeast RNA-editing deaminase provides insight into the fold and
function of activation-induced deaminase and APOBEC-1. Proc Natl Acad
Sci U S A 101: 8114–8119.
15. Zaim J, Kierzek AM (2003) Domain organization of activation-induced cytidine
deaminase. Nat Immunol 4: 1153.
16. Ta VT, Nagaoka H, Catalan N, Durandy A, Fischer A, et al. (2003) AID mutant
analyses indicate requirement for class-switch-specific cofactors. Nat Immunol 4:
843–848.
17. Wedekind JE, Dance GS, Sowden MP, Smith HC (2003) Messenger RNA
editing in mammals: new members of the APOBEC family seeking roles in the
family business. Trends Genet 19: 207–216.
18. Huthoff H, Malim MH (2005) Cytidine deamination and resistance to retroviral
infection: towards a structural understanding of the APOBEC proteins. Virology
334: 147–153.
19. Prochnow C, Bransteitter R, Klein MG, Goodman MF, Chen XS (2006) The
APOBEC-2 crystal structure and functional implications for the deaminase AID.
Nature.
20. Huthoff H, Malim MH (2007) Identification of amino acid residues in
APOBEC3G required for regulation by HIV-1 Vif and virion encapsidation.
J Virol PMID. pp 17267497.
21. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of
spatial restraints. J Mol Biol 234: 779–815.
22. Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, et al. (2000)
Comparative protein structure modeling of genes and genomes. Annu Rev
Biophys Biomol Struct 29: 291–325.
23. Fiser A, Do RK, Sali A (2000) Modeling of loops in protein structures. Protein
Sci 9: 1753–1773.
24. Kabsch W, Sander C (1983) Dictionary of protein secondary structure: pattern
recognition of hydrogen-bonded and geometrical features. Biopolymers 22:
2577–2637.
25. McGuffin LJ, Bryson K, Jones DT (2000) The PSIPRED protein structure
prediction server. Bioinformatics 16: 404–405.
26. Bryson K, McGuffin LJ, Marsden RL, Ward JJ, Sodhi JS, et al. (2005) Protein
structure prediction servers at University College London. Nucleic Acids Res 33:
W36–W38.
27. Jones DT (1999) Protein secondary structure prediction based on position-
specific scoring matrices. J Mol Biol 292: 195–202.
28. Clamp M, Cuff J, Searle SM, Barton GJ (2004) The Jalview Java alignment
editor. Bioinformatics 20: 426–427.
29. Melo F, Feytmans E (1998) Assessing protein structures with a non-local atomic
interaction energy. J Mol Biol 277: 1141–1152.
30. Melo F, Feytmans E (1997) Novel knowledge-based mean force potential at
atomic level. J Mol Biol 267: 207–222.
31. Melo F, Devos D, Depiereux E, Feytmans E (1997) ANOLEA: a www server to
assess protein structures. Proc Int Conf Intell Syst Mol Biol 5: 187–190.
32. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983)
CHARMM: A Program for Macromolecular Energy, Minimization, and
Dynamics Calculations. J Comp Chem 4: 187–217.
33. MacKerell AD, Bashford D, Bellott M, Dunbrack RL, Evaseck JD, et al. (1998)
All-atom empirical potential for molecular modeling and dynamics studies of
proteins. J Phys Chem B 102: 3586–3616.
34. Guerois R, Nielsen JE, Serrano L (2002) Predicting changes in the stability of
proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol
320: 369–387.
35. Sanner MF, Olson AJ, Spehner JC (1996) Reduced surface: an efficient way to
compute molecular surfaces. Biopolymers 38: 305–320.
36. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, et al.
(2004) UCSF Chimera–a visualization system for exploratory research and
analysis. J Comput Chem 25: 1605–1612.
37. Davis ME, Madura JD, Luty BA, McCammon JA (1991) Electrostatics and
diffusion of molecules in solution: simulations with the University of Houston
Brownian Dynamics program. Comp Phys Comm 62: 187–197.
38. Navaratnam N, Bhattacharya S, Fujino T, Patel D, Jarmuz AL, et al. (1995)
Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase
that has acquired a novel RNA-binding motif at its active site. Cell 81: 187–195.
39. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telenti A (2006) Patterns of
evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3:
11.
40. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, et al. (2004) The interaction
between HIV-1 Gag and APOBEC3G. J Biol Chem 279: 33177–33184.
41. Schafer A, Bogerd HP, Cullen BR (2004) Specific packaging of APOBEC3G
into HIV-1 virions is mediated by the nucleocapsid domain of the gag
polyprotein precursor. Virology 328: 163–168.
42. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, et al. (2004) Human
apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APO-
BEC3G) is incorporated into HIV-1 virions through interactions with viral and
nonviral RNAs. J Biol Chem 279: 35822–35828.
43. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD (2004) APOBEC3G
incorporation into human immunodeficiency virus type 1 particles. J Virol 78:
12058–12061.
44. Conticello SG, Harris RS, Neuberger MS (2003) The Vif protein of HIV
triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
Curr Biol 13: 2009–2013.
45. Ohkura S, Yap MW, Sheldon T, Stoye JP (2006) All three variable regions of the
TRIM5 alpha B30.2 domain can contribute to the specificity of the retrovirus
restriction. J Virol 80: 8554–8565.
APOBEC3G Structure
PLoS ONE | www.plosone.org 7 April 2007 | Issue 4 | e378
